Fungal infections in the ICU: advances in treatment and diagnosis

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Mycology

Background:

• Severe invasive fungal infections pose a significant threat to critically ill patients in the Intensive Care Unit (ICU).
• Timely diagnosis and effective treatment are crucial to mitigate the clinical impact of these life-threatening conditions.

Purpose of the Study:

• To provide an updated overview of diagnostic methods for severe fungal diseases in the ICU.
• To review current therapeutic strategies for managing invasive fungal infections in critically ill patients.

Main Methods:

• Review of current literature on diagnostic approaches.
• Analysis of established and emerging therapeutic management strategies.
• Focus on biomarker-based diagnostic tools and first-line antifungal agents.

Main Results:

• Preemptive diagnostic strategies using serological markers, such as the (1-3)-β-D-glucan assay, are increasingly adopted over prophylactic or empirical methods.
• New diagnostic algorithms for aspergillosis leverage knowledge of galactomannan antigen kinetics.
• Echinocandins and voriconazole are recommended as first-line treatments for invasive Candida and Aspergillus infections, respectively.
• Other serious fungal pathogens like Pneumocystis jirovecii, Cryptococcus spp., and Mucorales spp. also require prompt attention.

Conclusions:

• Biomarker-guided diagnostics enable early detection of fungal infections and reduce inappropriate antifungal prescriptions.
• Effective and well-tolerated antifungal drugs are available, but careful consideration of treatment failure risks and new monitoring tools is necessary.